Panelists discuss how aflibercept’s molecular structure contributes to its clinical efficacy as a standard treatment for retinal vascular diseases.
Video content above is prompted by the following:
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.